EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility

Lucas Maciel de Almeida Corrêa, Gabriel Rian Mazur, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa, Ivan Felipe Dutra Júnior, Gabriel Costa de Santana, Luiggi Kevin Virgino Brandão, Yan Roberth Delmiro Silva, Letícia Esteves Dante

American Journal of Cardiovascular Drugs · 17.08.2026

DOI: 10.1007/s40256-026-00823-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Cardiovascular Drugs, online erschienen am 17.08.2026. Verfasst von Lucas Maciel de Almeida Corrêa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Av. Brigadeiro Faria Lima, 5544, São José do Rio Preto, SP, 15090-000…. Die Arbeit nennt 29 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Zilebesiran is an investigational RNA interference therapeutic that lowers blood pressure by silencing hepatic angiotensinogen, thereby offering sustained antihypertensive activity with infrequent dosing in selected ambulatory populations. This profile is attractive for long-term blood pressure control, but it also raises an unresolved clinical question: how should acute illness be managed when upstream renin-angiotensin system suppression cannot be rapidly attenuated? In this Current Opinion, we place that question in perspective using available trial data, cardiorenal physiology, and acute-care literature. Early-phase studies established that zilebesiran produces sustained angiotensinogen suppression and blood pressure reduction, while also showing that the antihypertensive response is modulated by dietary sodium intake and background renin-angiotensin-aldosterone system blockade. Phase 2 studies then confirmed antihypertensive efficacy in clinically stable outpatient populations, and KARDIA-3 extended evaluation to patients with uncontrolled hypertension and established or high cardiovascular risk receiving multiple antihypertensive agents; however, the study did not meet its prespecified multiplicity-adjusted threshold for statistical significance at month 3. The concern is not that harm has been demonstrated, but that prolonged angiotensinogen silencing may reduce short-term therapeutic flexibility during sepsis, perioperative stress, acute heart failure, marked volume depletion, or hyperkalemia-settings in which clinicians often rely on temporary adjustment of oral renin-angiotensin-aldosterone system inhibitors. Early reversal strategies are conceptually important, but current approaches appear better suited to planned de-escalation than emergency rescue. Future work should define vulnerable phenotypes, clarify whether acute-care pathways require protocol adaptation, and determine how reversibility can be operationalized as phase 3 development advances.

Autor:innen und Institutionen

  • Faculdade de Medicina de São José do Rio Preto (FAMERP), São José do Rio Preto, Av. Brigadeiro Faria Lima, 5544, São José do Rio Preto, SP, 15090-000, Brazil. lucasmacielll@icloud.com.
  • Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Paraná, Brazil.
  • Universidade Estadual de Mato Grosso do Sul (UEMS), Campo Grande, Mato Grosso do Sul, Brazil.
  • Universidade Salvador (UNIFACS), Salvador, Bahia, Brazil.
  • Centro Universitário Uninorte (UNINORTE), Rio Branco, Acre, Brazil.
  • Universidade Federal de Alagoas (UFAL), Arapiraca, Alagoas, Brazil.

Zitieren

APA

Corrêa, L. M. A., Mazur, G. R., Santiago, C. B. G., Barbosa, A. A., Dutra Júnior, I. F., de Santana, G. C., Brandão, L. K. V., Delmiro Silva, Y. R., & Dante, L. E. (2026). Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility. American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-026-00823-7

Vancouver

Corrêa LMA, Mazur GR, Santiago CBG, Barbosa AA, Dutra Júnior IF, de Santana GC, et al. Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility. American Journal of Cardiovascular Drugs. 2026. doi:10.1007/s40256-026-00823-7

BibTeX
@article{Corra2026,
  author = {Corrêa, Lucas Maciel de Almeida and Mazur, Gabriel Rian and Santiago, Clara Belo Gamon and Barbosa, Alexandre de Assis and Dutra Júnior, Ivan Felipe and de Santana, Gabriel Costa and Brandão, Luiggi Kevin Virgino and Delmiro Silva, Yan Roberth and Dante, Letícia Esteves},
  title = {Zilebesiran in Hypertension: Reversibility, Acute Illness, and Therapeutic Flexibility},
  journal = {American Journal of Cardiovascular Drugs},
  year = {2026},
  doi = {10.1007/s40256-026-00823-7}
}
Kostenlos starten →